3750 Stock Overview
Engages in the research, development, production, and sale of cell therapy related medical devices in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Cytori Cell Research Institute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥920.00 |
| 52 Week High | JP¥1,138.00 |
| 52 Week Low | JP¥777.00 |
| Beta | 0.18 |
| 1 Month Change | 5.38% |
| 3 Month Change | 12.06% |
| 1 Year Change | -16.21% |
| 3 Year Change | -24.53% |
| 5 Year Change | -7.35% |
| Change since IPO | -86.39% |
Recent News & Updates
Shareholder Returns
| 3750 | JP Real Estate | JP Market | |
|---|---|---|---|
| 7D | 3.0% | 0.2% | 0.8% |
| 1Y | -16.2% | 6.9% | 4.1% |
Return vs Industry: 3750 underperformed the JP Real Estate industry which returned 6.9% over the past year.
Return vs Market: 3750 underperformed the JP Market which returned 4.1% over the past year.
Price Volatility
| 3750 volatility | |
|---|---|
| 3750 Average Weekly Movement | 3.7% |
| Real Estate Industry Average Movement | 3.2% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 3750 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 3750's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 16 | Daichi Ito | www.cytori.co.jp |
Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn’s disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services.
Cytori Cell Research Institute, Inc. Fundamentals Summary
| 3750 fundamental statistics | |
|---|---|
| Market cap | JP¥8.21b |
| Earnings (TTM) | -JP¥61.00m |
| Revenue (TTM) | JP¥264.00m |
31.1x
P/S Ratio-134.7x
P/E RatioIs 3750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3750 income statement (TTM) | |
|---|---|
| Revenue | JP¥264.00m |
| Cost of Revenue | JP¥134.00m |
| Gross Profit | JP¥130.00m |
| Other Expenses | JP¥191.00m |
| Earnings | -JP¥61.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.83 |
| Gross Margin | 49.24% |
| Net Profit Margin | -23.11% |
| Debt/Equity Ratio | 131.8% |
How did 3750 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 13:37 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytori Cell Research Institute, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.